Traditional and non-traditional risk factors as contributors to atherosclerotic cardiovascular disease in end-stage renal disease

References

• Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epi-demiology and Prevention. Hypertension 2003; 42: 1050–65.
   PubMed Web of Science ®Google Scholar
• Pecoits-Filho R, Lindholm B, Stenvinkel P. The malnutrition, inflammation, and atherosclerosis (MIA) syndrome—the heart of the matter. Nephrol Dial Transplant 2002; 17 (Suppl 11): 28–31.
   Google Scholar
• Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. Hypoalbuminemia, cardiac morbidity, and mortality in end-stage renal disease. J Am Soc Nephrol 1996; 7: 728–36.
   PubMed Web of Science ®Google Scholar
• Lindner A, Charra B, Sherrard DJ, Scribner BH. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 1974; 290: 697–701.
   PubMed Web of Science ®Google Scholar
• Buzello M, Tomig J, Faulhaber J, Ehmke H, Ritz E, Amann K. The apolipoprotein E knockout mouse: a model documenting accelerated atherogenesis in uremia. J Am Soc Nephrol 2003; 14: 311–6.
   PubMed Web of Science ®Google Scholar
• Bro S, Bentzon if, Falk E, Andersen CB, Olgaard K, Nielsen LB. Chronic renal failure accelerates ather-ogenesis in apolipoprotein E-deficient mice. J Am Soc Nephrol 2003; 14: 2466–74.
   PubMed Web of Science ®Google Scholar
• Stenvinkel P. Pecoits-Filho R, Lindholm B. Coronary artery disease in end-stage renal disease: no longer a simple plumbing problem. J Am Soc Nephrol 2003; 14: 1927–39.
   Google Scholar
• Kato A, Takita T, Maruyama Y, Kumagai H, Hishida A. Impact of carotid atherosclerosis on long-term mortality in chronic hemodialysis patients. Kidney Int 2003; 64: 1472–9.
   Google Scholar
• Ganesh SK, Hulbert-Shearon T, Port FK, Eagle K, Stack AG. Mortality differences by dialysis modality among incident ESRD patients with and without coronary artery disease. J Am Soc Nephrol 2003; 14: 415–24.
   PubMed Web of Science ®Google Scholar
• Herzog CA, Ma JZ, Collins AJ. Comparative survival of dialysis patients in the United States after coronary angioplasty, coronary artery stenting, and coronary artery bypass surgery and impact of diabetes. Circulation 2002; 106: 2207–11.
   Google Scholar
• Jungers P. Massy ZA, Khoa TN, Fumeron C, Labrunie M, Lacour B, et al. Incidence and risk factors of atherosclerotic cardiovascular accidents in predialysis chronic renal failure patients: a prospective study. Nephrol Dial Transplant 1997; 12: 2597–602.
   PubMed Web of Science ®Google Scholar
• Rush H, Neugarten J, Coco M. Women's health issues in a dialysis population. Clin Nephrol 2000; 54: 455–62.
   Google Scholar
• Stenvinkel P, Wanner C, Metzger T, Heimbürger O, Mallamaci F, Tripepi G, et al. Inflammation and outcome in end-stage renal failure: does female gender constitute a survival advantage? Kidney Int 2002; 62: 1791–8.
   Google Scholar
• Cheung AK, Samak MJ, Yan G, Dwyer JT, Heyka RJ, Rocco MV, et al. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int 2000; 58: 353–62.
   PubMed Web of Science ®Google Scholar
• Orth SR, Ritz E. The renal risks of smoking: an update. Curr Opin Nephrol Hypertens 2002; 11: 483–8.
   PubMed Web of Science ®Google Scholar
• Koch M, Thomas B, Tschope W, Ritz E. Survival and predictors of death in dialysed diabetic patients. Diabetologia 1993; 36: 1113–7.
   PubMed Web of Science ®Google Scholar
• Foley RN, Herzog CA, Collins AJ, United States Renal Data System. Blood pressure and long-term mortality in United States hemodialysis patients: USRDS Waves 3 and 4 Study. Kidney Int 2002; 62: 1784–90.
   Google Scholar
• Merkus MP, Jager KJ, Dekker FW, de Haan RJ, Boeschoten EW, Krediet RT. Predictors of poor outcome in chronic dialysis patients: The Netherlands Cooperative Study on the Adequacy of Dialysis. The NECOSAD Study Group. Am J Kidney Dis 2000; 35: 69–79.
   Google Scholar
• Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. Impact of hypertension on cardio-myopathy, morbidity and mortality in end-stage renal disease. Kidney Int 1996; 49: 1379–85.
   PubMed Web of Science ®Google Scholar
• Charra B, Calemard E, Cuche M, Laurent G. Control of hypertension and prolonged survival on maintenance hemodialysis. Nephron 1983; 33: 96–9.
   PubMed Web of Science ®Google Scholar
• Harjai KJ. Potential new cardiovascular risk factors: left ventricular hypertrophy, homocysteine, lipoprotein(a), triglycerides, oxidative stress, and fibrinogen. Ann Intern Med 1999; 131: 376–86.
   PubMed Web of Science ®Google Scholar
• Sechi LA, Zingaro L, Catena C, Perin A, De Marchi S, Bartoli E. Lipoprotein(a) and apolipoprotein(a) isoforms and proteinuria in patients with moderate renal failure. Kidney Int 1999; 56: 1049–57.
   PubMed Web of Science ®Google Scholar
• Kronenberg F, Kuen E, Ritz E, Junker R, Konig P. Kraatz G, et al. Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure. J Am Soc Nephrol 2000; 11: 105–15.
   Google Scholar
• Cressman MD, Heyka RJ, Paganini EP, O'Neil J, Skibinski CI, Hoff HF. Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation 1992; 86: 475–82.
   Google Scholar
• Iliescu EA, Marcovina SM, Morton AR, Lam M, Koschinsky ML. Apolipoprotein(a) phenotype and lipoprotein(a) level predict peritoneal dialysis patient mortality. Penh Dial Int 2002; 22: 492–9.
   Google Scholar
• Allman PO, Samuelsson OG, Moberly J, Johansson AC, Ljungman S, Weiss LG, et al. Apolipoprotein B-containing lipoproteins in renal failure: the relation to mode of dialysis. Kidney Int 1999; 55: 1536–42.
   PubMed Web of Science ®Google Scholar
• Johansson AC, Samuelsson O, Allman PO, Haraldsson B, Moberly J, Knight-Gibson C, et al. Dyslipidemia in peritoneal dialysis-relation to dialytic variables. Petit Dial Int 2000; 20: 306–14.
   PubMed Web of Science ®Google Scholar
• Stompor T, Pasowicz M, Sullowicz W, Dembinska-Kiec A, Janda K, Wojcik K, et al. An association between coronary artery calcification score, lipid profile, and selected markers of chronic inflammation in ESRD patients treated with peritoneal dialysis. Am J Kidney Dis 2003; 41: 203–11.
   Google Scholar
• Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990; 15: 458–82.
   PubMed Web of Science ®Google Scholar
• Chang JW, Yang WS, MM WK, Lee SK, Park JS, Kim SB. Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients. Am J Kidney Dis 2002; 39: 1213–7.
   PubMed Web of Science ®Google Scholar
• Collins AJ, Li S, Ma JZ, Herzog C. Cardiovascular disease in end-stage renal disease patients. Am J Kidney Dis 2001; 38 (4 Suppl 1): S26–9.
   Google Scholar
• Mann If, Gerstein HC, Dulau-Florea I, Lonn E. Cardiovascular risk in patients with mild renal insuffi-ciency. Kidney Int Suppl 2003; 84: S192–6.
   Google Scholar
• Schwarz U, Buzello M, Ritz E, Stein G, Raabe G, Wiest G, et al. Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant 2000; 15: 218–23.
   PubMedGoogle Scholar
• Himmelfarb J, Stenvinkel P. Ikizler TA, Hakim RM. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002; 62: 1524–38.
   PubMed Web of Science ®Google Scholar
• Locatelli F, Canaud B, Eckardt KU, Stenvinkel P. Wanner C, Zoccali C. Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant 2003; 18: 1272–80.
   PubMed Web of Science ®Google Scholar
• Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001; 104: 2673–8.
   Google Scholar
• Drueke T, Witko-Sarsat V, Massy Z, Descamps-Latscha B, Guerin AP, Marchais SJ, et al. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 2002; 106: 2212–7.
   PubMed Web of Science ®Google Scholar
• Stenvinkel P. Diezfalusy U, Lindholm B, Heimbinger 0.53.Phospholipid plasmalogen, a surrogate marker of oxidative stress, is associated with increased cardiovas-cular mortality in patients on renal replacement therapy.54.Nephrol Dial Transplant 2004; 19: 972–6.
   Google Scholar
• Miyata T, Wada Y, Cai Z, Iida Y, Hone K, Yasuda Y, et al. Implication of an increased oxidative stress in the formation of advanced glyeation end products in55. patients with end-stage renal failure. Kidney Int 1997; 51: 1170–81.
   PubMed Web of Science ®Google Scholar
• Channon KM. Oxidative stress and coronary plaque stability. Arterioseler Thromb Vase Biol 2002; 22:56.1751–2.
   PubMedGoogle Scholar
• Axisa B, Loftus IM, Naylor AR, Goodall S, Jones L, Bell PR, et al. Prospective, randomized, double-blind trial investigating the effect of doxycycline on matrix57.metalloproteinase expression within atherosclerotic carotid plaques. Stroke 2002; 33: 2858–64.
   Google Scholar
• Nakata Y, Maeda N. Vulnerable atherosclerotic plaque morphology in apolipoprotein E-deficient mice unable to58.make ascorbic acid. Circulation 2002; 105: 1485–90.
   PubMed Web of Science ®Google Scholar
• Boaz M, Smetana S, Weinstein T, Matas Z, Gafter U, Iaina A, et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease59.(SPACE): randomized placebo-controlled trial. Lancet 2000; 3: 1213–8.
   Google Scholar
• Tepel M, van der Giet M, Statz M, Jankowski J, Zidek W. The antioxidant aeetyleysteine reduces cardiovascu-lar events in patients with end-stage renal failure: a60.randomized, controlled trial. Circulation 2003; 107: 992–5.
   Google Scholar
• Stenvinkel P. Interactions between inflammation, oxida-tive stress, and endothelial dysfunction in end-stage renal61.disease. J Ren Nutr 2003; 13: 144–8.
   PubMed Web of Science ®Google Scholar
• Brennan ML, Penn MS, Van Lente F, Nambi V, Shishehbor MH, Aviles RJ, et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J62.Med 2003; 349: 1595–604.
   PubMed Web of Science ®Google Scholar
• Baldus S, Heesehen C, Meinertz T, Zeiher AM, Eiserich JP, Munzel T, et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes.63.Circulation 2003; 108: 1440–5.
   PubMed Web of Science ®Google Scholar
• Himmelfarb J, McMenamin ME, Loseto G, Heineeke JVV. Myeloperoxidase-catalyzed 3-chlorotyrosine forma-tion in dialysis patients. Free Radie Biol Med 2001; 31:64.1163–9.
   PubMedGoogle Scholar
• Piedrafita FJ, Molander RB, Vansant G, Orlova EA, Pfahl M, Reynolds WF. An Alu element in the65.myeloperoxidase promoter contains a composite SP1-thyroid hormone-retinoie acid response element. J Biol Chem 1996; 271: 14412–20.
   Google Scholar
• Nikpoor B, Tureeki G, Fournier C, Theroux P, Rouleau66.GA. A functional myeloperoxidase polymorphic variant is associated with coronary artery disease in French-Canadians. Am Heart J 2001; 142: 336–9.
   Google Scholar
• Peeoits-Filho R, Stenvinkel P. Marehlewska A,67.Heimbitrger O, Barany P, Hoff CM, et al. A functional variant of the myeloperoxidase gene is associated with cardiovascular disease in end-stage renal disease patients. Kidney Int Suppl 2003; 84: S172–6.68.
   Google Scholar
• Stenvinkel P. Holmberg I, Heimbinger O, Diezfalusy U. A study of plasmalogen as an index of oxidative stress in patients with chronic renal failure. Evidence of increased oxidative stress in malnourished patients.69.Nephrol Dial Transplant 1998; 13: 2594–600.
   Google Scholar
• Stenvinkel P. Alvestrand A. Inflammation in end-stage renal disease: sources, consequences, and therapy. Semin Dial 2002; 15: 329–37.
   Google Scholar
• Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999; 55: 648–58.
   PubMed Web of Science ®Google Scholar
• Peeoits-Filho R, Barany P. Lindholm B, Heimbinger O, Stenvinkel P. Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. Nephrol Dial Transplant 2002; 17: 1684–8.
   Google Scholar
• Stenvinkel P. Heimburger O, Wang T, Lindholm B, Bergstrom J, Elinder CG. High serum hyaluronan indicates poor survival in renal replacement therapy. Am J Kidney Dis 1999; 34: 1083–8.
   Google Scholar
• Zoccali C, Mallamaei F, Tripepi G, Cutrupi S, Parlongo S, Malatino LS, et al. Fibrinogen, mortality and incident cardiovascular complications in end-stage renal failure. J Intern Med 2003; 254: 132–9.
   PubMed Web of Science ®Google Scholar
• Reddan DN, Klassen PS, Szczech LA, Coladonato JA, O'Shea S, Owen WF, et al. White blood cells as a novel predictor in haemodialysis patients. Nephrol Dial Transpl 2003; 18: 1167–73.
   PubMed Web of Science ®Google Scholar
• Chang MK, Binder CJ, Torzewski M, Witztum JL. C-reactive protein binds to both oxidized LDL and apoptotie cells through recognition of a common ligand: phosphoryleholine of oxidized phospholipids. Proe Natl Aead Sei USA 2002; 99: 13043–8.
   PubMed Web of Science ®Google Scholar
• Venugopal SK, Devaraj S, Yuhanna I, Shaul P. halal I. Demonstration that C-reactive protein decreases eNOS expression and bioaetivity in human aortic endothelial cells. Circulation 2002; 106: 1439–41.
   Google Scholar
• Tintut Y, Patel J, Parhami F, Demer LL. Tumor necrosis factor-alpha promotes in vitro calcification of vascular cells via the cAMP pathway. Circulation 2000; 102: 2636–42.
   PubMed Web of Science ®Google Scholar
• Bologa RM, Levine DM, Parker TS, Cheigh JS, Serur D, Stenzel KH, et al. Interleukin-6 predicts hypoalbumine-mia, hypoeholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis 1998; 32: 107–14.
   PubMed Web of Science ®Google Scholar
• Stenvinkel P. Barany P. Heimbinger O, Peeoits-Filho R, Lindholm B. Mortality, malnutrition, and atherosclerosis in ESRD: what is the role of interleukin-6? Kidney Int Suppl 2002; 80: 103–8.
   Google Scholar
• Huber SA, Sakkinen P. Conze D, Hardin N, Tracy R. Interleukin-6 exacerbates early atherosclerosis in mice. Arterioseler Thromb Vase Biol 1999; 19: 2364–7.
   PubMed Web of Science ®Google Scholar
• Blankenberg S, Tiret L, Bickel C, Peetz D, Cambien F, Meyer J, et al. Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation 2002; 106: 24–30.
   PubMed Web of Science ®Google Scholar
• Girndt M, Kaul H, Sester U, Ulrich C, Sester M, Georg T, et al. Anti-inflammatory interleukin-10 genotype pro-tects dialysis patients from cardiovascular events. Kidney Int 2002; 62: 949–55.
   PubMed Web of Science ®Google Scholar
• Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342: 1478–83.
   PubMed Web of Science ®Google Scholar
• Blather J, Guerin AP, Pannier B, Marehais SJ, London GM. Arterial calcifications, arterial stiffness, and cardio-vascular risk in end-stage renal disease. Hypertension 2001; 38: 938–42.
   Google Scholar
• London GM, Guerin AP, Marehais SJ, Metivier F, Pannier B, Adda H. Arterial media calcification in Scand J Urol Nephrol 38 end-stage renal disease: impact on all-cause and cardio-vascular mortality. Nephrol Dial Transplant 2003; 18: 1731–40.
   PubMed Web of Science ®Google Scholar
• Wang AY, Wang M, Woo J, Lam CW, Li PK, Lui SF, et al. Cardiac valve calcification as an important predictor for all-cause mortality and cardiovascular mortality in long-term peritoneal dialysis patients: a prospective study. J Am Soc Nephrol 2003; 14: 159–68.
   PubMed Web of Science ®Google Scholar
• Vliegenthart R, Hollander M, Breteler MM, van der Kuip DA, Hofman A, Oudkerk M, et al. Stroke is associated with coronary calcification as detected by electron-beam CT: the Rotterdam Coronary Calcification Study. Stroke 2002; 33: 462–5.
   Google Scholar
• Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phos-phate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31: 607–17.
   PubMed Web of Science ®Google Scholar
• Rubel JR, Milford EL. The relationship between serum calcium and phosphate levels and cardiac valvular procedures in the hemodialysis population. Am J Kidney Dis 2003; 41: 411–21.
   PubMed Web of Science ®Google Scholar
• Wang AY, Woo J, Wang M, Sea MM, Ip R, Li PK, et al. Association of inflammation and malnutrition with cardiac valve calcification in continuous ambulatory peritoneal dialysis patients. J Am Soc Nephrol 2001; 12: 1927–36.
   PubMed Web of Science ®Google Scholar
• Oh J, Wunsch R, Turzer M, Balmer M, Raggi P. Querfeld U, et al. Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Circulation 2002; 106: 100–5.
   Google Scholar
• Ketteler M, Bongartz P. Westenfeld R, Wildberger JE, Mahnken AH, Bohm R, et al. Association of low fetuin-A (AHSG) concentrations in serum with cardio-vascular mortality in patients on dialysis: a cross-sectional study. Lancet 2003; 361: 827–33.
   PubMed Web of Science ®Google Scholar
• Martola L, Elinder C-G, Stenvinkel P. Varftir far njursjuka ett hjärta av sten? Störd kalk-fosfatbalans och inflammation viktiga orsaker. Läkartidningen 2003; 50: 4180–3.
   Google Scholar
• Nitta K, Akiba T, Uchida K, Kawashima A, Yumura W, Kabaya T, et al. The progression of vascular calcification and serum osteoprotegerin levels inpatients on long-term hemodialysis. Am J Kidney Dis 2003; 42: 303–9.
   PubMed Web of Science ®Google Scholar
• Zoccali C, Mallamaci F, Asahia K, Benedetto FA, Tripepi G, Tripepi R, et al. Pentosidine, carotid atherosclerosis and alterations in left ventricular geom-etry in hemodialysis patients. J Nephrol 2001; 14: 293–8.
   PubMed Web of Science ®Google Scholar
• Suliman ME, Heimbitrger O, Barany P. Anderstam B, Pecoits-Filho R, Rodriguez Ayala E, et al. Plasma pentosidine is associated with inflammation and mal-nutrition in end-stage renal disease patients starting on dialysis therapy. J Am Soc Nephrol 2003; 14: 1614–22.
   Google Scholar
• Schwedler SB, Metzger T, Schinzel R, Wanner C. Advanced glyeation end products and mortality in hemodialysis patients. Kidney Int 2002; 62: 301–10.
   PubMed Web of Science ®Google Scholar
• Uribarri J, Peppa M, Cai W, Goldberg T, Lu M, He C, et al. Restriction of dietary glycotoxins reduces exces-sive advanced glyeation end products in renal failure patients. J Am Soc Nephrol 2003; 14: 728–31.
   PubMed Web of Science ®Google Scholar
• Iseki K, Yamazato M, Tozawa M, Takishita S. Hypo-cholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. Kidney Int 2002; 61: 1887–93.
   PubMed Web of Science ®Google Scholar
• Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997; 337: 230–6.
   PubMed Web of Science ®Google Scholar
• Suliman ME, Qureshi AR, Barany P. Stenvinkel P. Filho JC, Anderstam B, et al. Hyperhomocysteinemia, nutri-tional status, and cardiovascular disease in hemodialysis patients. Kidney Int 2000; 57: 1727–35.
   Google Scholar
• Wrone EM, Zehnder it, Hornberger JM, McCann LM, Coplon NS, Fortmann SP. An MTHFR variant, homo-cysteine, and cardiovascular comorbidity in renal disease. Kidney Int 2001; 60: 1106–13.
   PubMed Web of Science ®Google Scholar
• Lowrie EG, Li Z, Ofsthun N, Lazarus IM. Body size, dialysis dose and death risk relationships among hemo-dialysis patients. Kidney Int 2002; 62: 1891–7.
   PubMed Web of Science ®Google Scholar
• Coresh J, Longenecker JC, Miller ER 3rd, Young HJ, Klag MJ. Epidemiology of cardiovascular risk factors in chronic renal disease. J Am Soc Nephrol 1998; 9 (12 Suppl): S24–30.
   Google Scholar
• Kalantar-Zadeh K, Kopple JD. Relative contributions of nutrition and inflammation to clinical outcome in dialysis patients. Am J Kidney Dis 2001; 38: 1343–50.
   Google Scholar
• Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 2003; 63: 793–808.
   PubMed Web of Science ®Google Scholar
• Ruilope LM, Salvetti A, Jamerson K, Hansson L, Wamold I, Wedel H, et al. Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. J Am Soc Nephrol 2001; 12: 218–25.
   PubMed Web of Science ®Google Scholar
• Stenvinkel P. Heimbinger O, Lindholm B, Kaysen GA, Bergstrom J. Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome). Nephrol Dial Transplant 2000; 15: 953–60.
   Google Scholar
• Iseki K, Miyasato F, Tokuyama K, Nishime K, Uehara H, Shiohira Y, et al. Low diastolic blood pressure, hypo-albuminemia, and risk of death in a cohort of chronic hemodialysis patients. Kidney Int 1997; 51: 1212–7.
   PubMed Web of Science ®Google Scholar